A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of INV-001 Administration for the Prevention of Scar After Thyroidectomy

The goal of this study is to evaluate the efficacy and Safety of INV-001 administration for the prevention of scar after thyroidectomy.
Participants will be asked to apply ointment on their scar for 12 weeks.

开始日期2023-02-14

申办/合作机构

Innovo Therapeutics Co., Ltd.初创企业

100 项与 INV-001 相关的临床结果

登录后查看更多信息

100 项与 INV-001 相关的转化医学

登录后查看更多信息

100 项与 INV-001 相关的专利（医药）

登录后查看更多信息

项与 INV-001 相关的文献（医药）

Scientific Reports

Analysis on efficacy of magnetic resonance lymphangiography using INV-001 in healthy beagle dogs

Article

作者: Park, Hyo Jung ; Shin, Tae-Hyun ; Kim, Nari ; Jang, Ji Sung ; Lee, Do-Wan ; Kim, Kyung Won ; Kim, Mi-Hyun ; Kim, Ji-Wook

AbstractWe aimed to conduct a proof-of-concept study of INV-001 in visualizing lymphatic vessels and nodes without venous contamination and to determine the optimal dose condition of INV-001 for magnetic resonance lymphangiography (MRL) in healthy beagles. MRL was performed using a 3.0-Tesla (T) whole body clinical magnetic resonance imaging (MRI) scanner. A dose-finding study of INV-001 for MRL in beagles (N = 6) was carried out according to an adaptive optimal dose finding design. For the reproducibility study (N = 6), MRL was conducted at selected INV-001 doses (0.056 and 0.112 mg Fe/kg) with a 15 mM concentration. Additionally, an excretion study (N = 3) of INV-001 was conducted by analyzing T1, T2, and T2* maps of the liver and kidney 48 h post-administration. INV-001 administration at doses of 0.056 and 0.112 mg Fe/kg (concentration: 15 mM) consistently demonstrated the visualization of contrast-enhanced lymphatic vessels and nodes without venous contamination in the beagles. The contrast enhancement effect was highest at 30 min after INV-001 administration, then gradually decreasing. No toxicity-related issues were identified during the study. After 48 h, the T1, T2, and T2* values in the liver and both kidneys were found to be comparable to the pre-administration values, indicating thorough INV-001 excretion. The optimal dosing conditions of INV-001 for MRL for contrast-enhanced visualization of lymphatic vessels and nodes exclusively with no venous contamination in beagles was determined to be 0.056 mg Fe/kg with a 15 mM concentration.

100 项与 INV-001 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
瘢痕	临床2期	-	Innovo Therapeutics Co., Ltd.初创企业	2022-11-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05838833 (PipelineReview) 人工标引	临床2期	瘢痕	77	INV-001	襯廠鹽選夢網鹽醖齋憲(膚觸獵鏇廠廠鹽鏇繭鏇) = A trend of lower scores was observed in each treatment group compared to the placebo. Additionally, the within-group score change from baseline to 12 weeks was statistically significantly reduced in the high-dose (2%) treatment group. 鑰獵壓鑰獵糧範憲網醖 (廠醖製鑰範鹹襯蓋簾構 ) 更多	积极	2024-08-21
				Placebo